RobinKDoreMD

PubMed

• 400 citations
  Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blin...
  Stanley Cohen, Robin K. Dore, Nancy E Lane, Peter A. Ory, Charles G. Peterfy
  Arthritis and Rheumatism. 2008-05-01
• 110 citations
  ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis
  Henry G. Bone, Felicia Cosman, Paul D. Miller, Gregory C. Williams, Gary Hattersley
  The Journal of Clinical Endocrinology and Metabolism. 2018-08-01
• 90 citations
  Reduced risk of back pain following teriparatide treatment: a meta-analysis.
  Michael C. Nevitt, Peiqi Chen, Robin K. Dore, Jean-Yves Reginster, Douglas P. Kiel
  Osteoporosis International. 2006-02-01

Journal Articles

• Osteoporosis: Fractures and Key Risk Factors.  
  Dore RK, Female Patient; March Supp:5-12
• Guidelines for Rheumatology Referral.  
  Dore RK, et al, American College of Rheumatology
• Efficacy and Safety of Etodolac and Naproxen in Patients with Osteoarthritis of the Knee: A Double-Blind, Placebo Controlled Study.  
  Dore RK, et al, Clinical Therapeutics, Vol. 17, No 4, 656-666
• Generalized Morphia with Peripheral Eosinophilic Fasciitis and Myositis.  
  King DF, Dore RK, Gilbert DJ, Gurevitch AW, and Hirosi FM, Intemational J. DermatoI_19:149-154
• Join now to see all

Books/Book Chapters

• Arthritis: your comprehensive guide to pain management, medication, diet, exercise, surgery, and physical therapies. 
  Bird H, Green C et al. US Consultant: Dore RKDK Publishing, New York
• Bone Disease in Rheumatology. 
  Chapter: The Use of Parathyroid Hormone in Patients with Rheumatic Diseases 
  Dore RKEditors: Maricic MJ, Gluck 0.Lippincott Williams & Wilkins, Philadelphia, PA
• Treatment of the Rheumatic Disease. 
  Chapter: Developing Medical Documentation for Rheumatology Encounters 
  Locks CD, Dore RKEditors: Weisman M, Weinblatt M, Louie J.WB Saunders, Philadelphia, PAEdition 2nd,

Abstracts/Posters

• Denosumab Increases Bone Mineral Density in Patients With Rheumatoid Arthritis: 12-month Results.
  Dore R et al, ASBMR
• Inhibiting RANKL with Denosumab Increases Bone Mineral Density in Patients with Rheumatoid Arthritis: 6month results from a randomized, placebo-controlled study.
  Dore RK et al, EULAR
• RANKL Inhibition with Denosumab Increases Bone Mineral Density in Patients with Rheumatoid Arthritis.
  Dore RK et al, ECCEO, Porto, Portugal
• Denosumab Increases Bone Mineral Density in Patients With Rheumatoid Arthritis.
  Dore RK et ai, ACR, Washington, DC
• Reasons for Patient Preferences for Once-Monthly Ibandronate.
  Dore RK, ASBMR, Philadelphia, PA
• Patient Preferences with a Once-Monthly Bisphosphonate.
  Dore RK, Congress on Osteoporosis, Toronto
• Liquid Enbrel improves Function and Health Related Quality of Life for Patients with Rheumatoid Arthritis.
  Dore R, et al, EULAR, Vienna, Austria
• The Safety and Efficacy Profile of Etanercept (ENBREL) Liquid Administered Once Weekly in Patients With Rheumatoid Arthritis.
  RK Dore, et al, ACR Annual Scientific Meeting, San Antonio TX
• Reduced Risk of Back Pain following Teriparatide Treatment: A Meta-analysis.
  RK Dore, et al, ACR Annual Scientific Meeting, San Antonio TX
• Reduction in Back Pain following Teriparatide compared with Alendronate treatment of postmenopausal women with osteoporosis.
  RK Dore, JH Krege, P Chen et al, 31st European Symposium on Caloified Tissues, Nice, France
• The safety of anakinra in combination with other RA therapies.
  Tesser J, Schectman J, Dore R et al for the 757 Study Group, EULAR
• Cevimeiine for the treatment of xerostomia in patients with Sjogren syndrome: a randomized trial.
  Fife R, Chase WF, Dore RK et al, Arch /ntem Med
• Changes in Bone Mineral Density 18 Months After Cessation of Recombinant Human Parathyroid Hormone (1-34) or Alendronate Treatment in Postmenopausal Women.
  Dore RK, Hodsman AB, et al, ACR, San Francisco
• A Profile of Lymphocytotoxic Antibodies in Systemic Lupus Erythematosus.
  Dore RK, Nies, KM, lwaki Y, Louie JS, Terasaki P, Clinical Research
• A Profile of Lymphocytotoxic Antibodies in Systemic Lupus Erythematosus.
  Dore RK, Nies KM, lwaki Y, Louie JS, Terasaki P, American Rheumatism National Meetings, Atlanta, GA
• Join now to see all